Another study demonstrated that TGFBR3 has anticancer properties in ccRCC independent of TGF-β and its canonical mechanism of action, and that loss of this receptor may occur early during RCC carcinogenesis [143]. This evidence concerns the gene TGFB1 and nonpapillary renal cell carcinoma.